Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 20/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 10/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4283058 | 1.00 | CACNA1B (0.61) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4277841 | 0.97 | CACNA1B (0.60) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4277616 | 0.83 | CACNA1B (0.60) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL15103559 | 0.82 | CACNA1B (0.60) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL13221492 | 0.82 | CACNA1B (0.60) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL3486136 | 0.82 | CACNA1B (0.68) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4396810 | 0.81 | CACNA1B (0.63) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4285121 | 0.80 | CACNA1B (0.61) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4388336 | 0.80 | CACNA1B (0.58) | CACNA1BNR1I2CYP3A4 | |
| SCHEMBL4394345 | 0.80 | CACNA1B (0.58) | CACNA1BNR1I2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9000174-B2 | 4-phenylsulfonamidopiperidines as calcium channel blockers | PURDUE PHARMA L.P. (US) | 2015-04-07 | — | — | US | disclosed |
| EP-1814851-B1 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO CELTIQUE SA (LU) | 2013-06-05 | — | — | EP | disclosed |
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | EURO-CELTIQUE S.A. (LU) | 2009-04-23 | — | — | US | disclosed |
| EP-1814851-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006040181-A2 | 4-PHENYLSULFONAMIDOPIPERIDINES AS CALCIUM CHANNEL BLOCKERS | EURO-CELTIQUE S.A. (LU) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105249-A1 | 4-phenylsulfonamidopiperidines as calcium channel blockers | CACNA1A, CACNA1E, CACNA1B | CACNA1B 3/4885NR1I2 1898/4885CYP3A4 1097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.